Selexipag 1.2 MG Oral Tablet — RxCUI 1729027
RxNorm drug concept · Semantic clinical drug
RxCUI 1729027
Semantic clinical drug · SCD
● Current RxNorm concept 30 FDA products
33 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1729027
Official nameSelexipag 1.2 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asselexipag 1200 MCG Oral Tablet
FDA products mapped30
Package NDCs mapped33
Reported Medicaid activity (SDUD)8,761 prescriptions · 34 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Selexipag: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Selexipag treats pulmonary arterial hypertension, a type of high blood pressure in the arteries of your lungs. It helps delay the disease getting worse and lowers the chance you'll...
- Tablets are taken by mouth twice a day and swallowed whole, so don't split or crush them. Taking them with food may help you tolerate them. Your doctor will raise your dose slowly,...
- Headache, diarrhea, nausea, jaw pain and muscle aches are common, especially while your dose is going up. Tell your doctor or pharmacist if they become hard to handle, since the do...
- Call right away if you have new or worsening shortness of breath, which could be fluid in the lungs. Also report symptoms that might suggest an overactive thyroid, or signs of an a...
🕸️ Concept Web — How Selexipag 1.2 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Selexipag 1.2 MG Oral Tablet
RxCUI 1729027 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Selexipag
1729002IN
-
Selexipag
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Uptravi
1729008BN
-
Uptravi
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Selexipag Oral Tablet
1729006SCDF -
Selexipag Oral Product
1729004SCDG -
Selexipag Pill
1729005SCDG -
Selexipag Oral Tablet [Uptravi]
1729010SBDF -
Uptravi Oral Product
1729011SBDG -
Uptravi Pill
1729012SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Selexipag Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Selexipag 1.2 MG
1729026SCDC -
Selexipag 1.2 MG Oral Tablet [Uptravi]
1729029SBD -
Selexipag 1.2 MG [Uptravi]
1729028SBDC
-
Selexipag 1.2 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Selexipag 1.2 MG
SCDC · 1729026 -
Selexipag Oral Tablet
SCDF · 1729006 -
Selexipag Oral Product
SCDG · 1729004 -
Selexipag Pill
SCDG · 1729005
Brand-Name Concepts
-
Selexipag 1.2 MG Oral Tablet [Uptravi]
SBD · 1729029 -
Selexipag 1.2 MG [Uptravi]
SBDC · 1729028 -
Selexipag Oral Tablet [Uptravi]
SBDF · 1729010 -
Uptravi Oral Product
SBDG · 1729011 -
Uptravi Pill
SBDG · 1729012 -
Uptravi
BN · 1729008
📦 FDA Products & Package NDCs
30 products · 33 package NDCs
33 package NDCs map to RxCUI 1729027 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 66215-0602-06 | 1 BOTTLE in 1 CARTON (66215-602-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0602-14 | 1 BOTTLE in 1 CARTON (66215-602-14) / 140 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0604-06 | 1 BOTTLE in 1 CARTON (66215-604-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0606-06 | 1 BOTTLE in 1 CARTON (66215-606-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0608-06 | 1 BOTTLE in 1 CARTON (66215-608-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0610-06 | 1 BOTTLE in 1 CARTON (66215-610-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0612-06 | 1 BOTTLE in 1 CARTON (66215-612-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0614-06 | 1 BOTTLE in 1 CARTON (66215-614-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0616-06 | 1 BOTTLE in 1 CARTON (66215-616-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0628-20 | 1 KIT in 1 CARTON (66215-628-20) * 1 BOTTLE in 1 CARTON /... | UPTRAVI Titration Pack | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0718-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) / 10 mL in 1... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2021-07-29 |
| 66215-0910-14 | 1 BOTTLE in 1 CARTON (66215-910-14) / 140 TABLET, FILM COAT... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2026-05-23 |
| 66215-0915-14 | 1 BOTTLE in 1 CARTON (66215-915-14) / 140 TABLET, FILM COAT... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2026-05-23 |
| 70710-1551-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1551-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1551-08 | 140 TABLET, FILM COATED in 1 BOTTLE (70710-1551-8) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1552-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1552-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1553-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1553-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1554-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1554-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1555-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1555-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1556-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1556-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1557-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1557-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1558-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70710-1558-6) | Selexipag | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70710-1653-07 | 1 KIT in 1 CARTON (70710-1653-7) * 1 BOTTLE in 1 CARTON /... | Selexipag TITRATION PACK | Zydus Pharmaceuticals (USA) Inc. | 2025-02-14 |
| 70771-1793-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1793-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1793-08 | 140 TABLET, FILM COATED in 1 BOTTLE (70771-1793-8) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1794-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1794-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1795-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1795-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1796-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1796-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1797-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1797-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1798-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1798-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1799-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1799-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1800-06 | 60 TABLET, FILM COATED in 1 BOTTLE (70771-1800-6) | Selexipag | Zydus Lifesciences Limited | 2025-02-14 |
| 70771-1801-07 | 1 KIT in 1 CARTON (70771-1801-7) * 1 BOTTLE in 1 CARTON /... | Selexipag TITRATION PACK | Zydus Lifesciences Limited | 2025-02-14 |
Observed labelers:
Actelion Pharmaceuticals US, Inc. (13) ·
Zydus Lifesciences Limited (10) ·
Zydus Pharmaceuticals (USA) Inc. (10)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.